ATLANTA (GenomeWeb) – A next-generation TRK inhibitor has yielded promising early results in cancer patients with NTRK gene fusions who had become resistant to other drugs that block the TRK protein.
ATLANTA (GenomeWeb) – A next-generation TRK inhibitor has yielded promising early results in cancer patients with NTRK gene fusions who had become resistant to other drugs that block the TRK protein.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.